http://www.baxter.com/about_baxter/news_room/news_releases/index.html
Baxter announced the FDA has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for treatment of bleeding episodes in adults with acquired hemophilia A, a very rare and potentially life-threatening acute bleeding disorder. OBIZUR was granted orphan-drug status by the FDA. October 24, 2014